In March 2025, Isomorphic Labs raised $600m via a financing round led by Thrive Capital, which has been used to continue developing the AI drug-design engine and advance the pipeline into clinical ...

Alphabet has now taken that advancement and created a new company called Isomorphic Labs, focused on AI-driven drug discovery. This commercial venture was founded and is currently led by DeepMind ...

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

Google parent company Alphabet is launching a new company called Isomorphic Laboratories which will use AI tools for drug discovery. It will build off the protein folding work from DeepMind.

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical programs, and accelerate disease research. Close. Latest News; ...

Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with ...

Isomorphic announced on Monday that it had raised $600 million, led by Thrive Capital, the venture capital firm that has bet big on A.I. companies including OpenAI.

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune.Born from DeepMind’s AlphaFold breakthrough, the company is ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led ...